VICO

A multi-centre randomized open label trial on the safety and efficacy of chloroquine for the treatment of hospitalized adults with laboratory confirmed SARS-CoV-2 infection in Vietnam

This study in Vietnam will evaluate whether chloroquine decreases the SARS-CoV-2 viral load in adults hospitalized with lab-confirmed COVID-19.

Primary objective: To assess if Chloroquine results in a more rapid decline in viral load in throat/nose swabs in patients with COVID-19

 

Type of study: Phase II trial, therapeutics

 

Treatment tested: Chloroquine

 

Countries: Vietnam

 

Number of sites: 5

 

Sample size: 240

 

Study participants: Hospitalized adults with laboratory confirmed SARS-CoV-2 infection

 

Study status: Recruiting

 

Principal investigators

  • Dr Vinh Chau, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
  • Prof. Jeremy Day, University of Oxford, UK

 

More information

 

 

Last updated: July 2020

 

 

Disclaimer
Note that study-related documents posted on the COVID-19 Clinical Research Coalition (COVID-19 CRC) website have been shared by coalition members for information. Some may have been approved by Ethics Review Boards and others may still be in draft form. Documents posted here may have been further amended before being used in the conduct of the respective trials they were designed for. It is recommended that users review these documents carefully and, if they plan to use them, adapt them appropriately for their intended use. The COVID-19 CRC and its members cannot accept any liability for any claim, loss or damages as a result of any reliance placed on, or use of, these documents.